Is Australia lagging behind in the use of neoadjuvant chemotherapy for breast cancer?

David R. G. Littlejohn


Neoadjuvant chemotherapy (NAC) is an important treatment option for patients with breast cancer. This paper utilises data from the Breast Surgeons of Australia and New Zealand Quality Audit (BQA). This is a large bi-national audit which collects approximately 80% of all breast cancer cases in Australia and New Zealand. Although data from the BQA is encouraging with NAC use more than doubling from 2011 to 2016 (3.08% to 6.65%) in many centres it remains an underutilized option.